Phase 3 Study of Surgery Combined With Neoadjuvant Chemotherapy(XELOX) in Colorectal Cancer With Resectable Liver Metastasis

Last updated: March 5, 2008
Sponsor: Peking University People's Hospital
Overall Status: Trial Status Unknown

Phase

3

Condition

Neoplasm Metastasis

Colon Cancer; Rectal Cancer

Liver Cancer

Treatment

N/A

Clinical Study ID

NCT00630045
OXALIC
  • Ages 18-75
  • All Genders

Study Summary

This study aims to discuss the efficacy and safety of neoadjuvant chemotherapy with XELOX regimen (oxaliplatin plus capecitabine) .

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Histologically confirmed colorectal cancer with liver metastasis(all patients shouldhave the pathological report of colorectal cancer. The chances of hepatocellularcarcinoma or metastasis from other primary lesions should be excluded. )

  2. Liver metastasis should be resected with R0 resection and to save enough normal livertissue

  3. Anticipated liver resection: for normal liver, ﹤70%; for liver with cirrhosis, ﹤50%

  4. No metastasis of other organs or lymph nodes in abdominal cavity

  5. No previous use of oxaliplatin and capecitabine, or previous adjuvant treatment endedmore than 6 months

  6. Age 18 to 75 years old

  7. Karnofsky performance status ≥70

  8. Life expectancy of ≥3 month

  9. Bilirubin level < 1.5mg/dL

  10. Serum creatinine <1.0 times ULN

  11. Absolute neutrophil count ≥2000/mm3, platelet>100,000/mm3, Hb>9g/dl

  12. Having signed informed consent

Exclusion

Exclusion Criteria:

  1. previous use of oxaliplatin or fluorouracil-based chemotherapy in 6 months.

  2. No R0 resection or not enough normal liver tissue left

  3. previous radiotherapy of target lesions

  4. accompanied with unresectable other metastasis or malignant pleural fluids or ascites.

  5. complete or uncompleted liver obstruction

  6. peripheral neuropathy(NCI-CTC grade 1 or more)

  7. mental disturbance neuropathy that influence the cognition, including brain metastasis

  8. other serious disease such as uncontrollable active infection, heart infarction with 1year, un controlled hypertension, arrhythmia with high risk, or unstable heartinfarction,heart failure, coronary artery disease, myocardial infarction within thelast 6 months

  9. Other previous malignancy within 5 year, except non-melanoma skin cancer

  10. accompany with other anti-tumor therapies,including immune therapy, intervention orinjection with chemotherapeutical agents into serous cavity, or participating otherclinical trials.

  11. Pregnancy or lactation period

Study Design

Total Participants: 392
Study Start date:
January 01, 2008
Estimated Completion Date:
June 30, 2015

Study Description

Liver metastasis is the most important prognostic factor of colorectal cancer. Reasonable multidisciplinary therapy might improve the prognosis of patients with liver metastasis. Surgery has been the first choice under such situation. Recently, neoadjuvant chemotherapy has also shown its value in unresectable liver metastasis, for it can increase the chance of R0 resection and give some clues to chemosensitivity of agents. However, for those resectable lesions, the role and safety of neoadjuvant chemotherapy has yet to be confirmed. so we design this study.

Connect with a study center

  • Peking University, School of Oncology

    Beijing, Beijing 100036
    China

    Active - Recruiting

  • Peking University, People's Hospital

    Beijing, 100044
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.